These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Private rights to adulterated/misbranded articles. McMonagle L. AIDS Public Policy J; 1987; 2(2):33-49. PubMed ID: 11650029 [No Abstract] [Full Text] [Related]
7. Laetrile: the battle moves into the courtroom. Schwartz RL. Am Bar Assoc J; 1979 Feb; 65():224-8. PubMed ID: 11661617 [No Abstract] [Full Text] [Related]
8. Regulation of drug treatments for HIV and AIDS: a contractarian model of access. Salbu SR. Yale J Regul; 1994 Feb; 11(2):401-53. PubMed ID: 11660141 [No Abstract] [Full Text] [Related]
15. F.D.A., in big shift, will permit use of experimental AIDS drug. Hilts PJ. N Y Times Web; 1989 Sep 29; ():A1, A16. PubMed ID: 11646735 [No Abstract] [Full Text] [Related]
16. The scarlet letter "A": AIDS in a computer society. van Dam MN. Comput Law J; 1990 Apr 29; 10(2):233-64. PubMed ID: 11653972 [No Abstract] [Full Text] [Related]
17. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures. Dunbar MM. Food Drug Cosmet Law J; 1991 Sep 29; 46(5):673-706. PubMed ID: 11651380 [No Abstract] [Full Text] [Related]
18. Implications of the federal drug investigation and approval processes for the development and availability of AIDS treatments and vaccines. Mathers PR. AIDS Public Policy J; 1987 Sep 29; 2(2):50-3. PubMed ID: 11650030 [No Abstract] [Full Text] [Related]